Zontivity
My Prescription
Payment
Select pharmacy
We couldn’t generate a coupon right now. Please try again later.
WalmartPowered byAbout Zontivity
Drug Details
Vorapaxar, marketed as Zontivity, is an antiplatelet medication prescribed to reduce the risk of heart attacks and strokes in individuals who have previously experienced a heart attack or suffer from peripheral artery disease (PAD). It functions by inhibiting the clumping of platelets, which are blood cells crucial for clot formation. This action helps prevent the formation of harmful clots that can obstruct blood flow, potentially leading to serious health issues like strokes and heart attacks. Vorapaxar is typically administered once daily and is taken alongside clopidogrel (Plavix), aspirin, or both to enhance its efficacy in maintaining smooth blood circulation. Always consult with healthcare professionals before starting or altering any medication regimen.
Price history for Zontivity
30 Tablets, 2.08MG
Average retail price for Zontivity
Average SaveHealth price for Zontivity
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Zontivity dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 2.08MG | 30 Tablets | $483.58 | $16.12 |
| 2.08MG | 90 Tablets | $1,424.11 | $15.82 |
Zontivity FAQs
Zontivity is used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or with peripheral arterial disease. It works by inhibiting platelet aggregation, which helps prevent blood clots.
Zontivity (vorapaxar) works by inhibiting the protease-activated receptor-1 (PAR-1) on platelets. This action prevents thrombin-induced platelet aggregation, thereby reducing the risk of thrombotic cardiovascular events.
Vorapaxar is classified as a protease-activated receptor-1 (PAR-1) antagonist. It is used to reduce the risk of thrombotic cardiovascular events.
Yes, vorapaxar is FDA approved. It was approved by the U.S. Food and Drug Administration for use in reducing thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.
Zontivity is indicated to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease.